Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the ...
RTX-240, Rubius Therapeutics' lead oncology program, is an allogeneic, off-the-shelf cellular therapy product candidate that is engineered to simultaneously present hundreds of thousands of copies of ...
Rubius Therapeutics has pulled the plug on its lead drug after its first use in a phase 1b generated “uninterpretable” data. The data capped off a series of setbacks for the phenylketonuria (PKU) ...
Enthusiasm in the immuno-oncology therapies being developed by Rubius Therapeutics has allowed the biotech to quickly raise $220 million, a large chunk of which it will invest in a cell therapy ...
* RUBIUS THERAPEUTICS - COMPLETED DOSING OF FIRST DOSE-ESCALATION COHORT WITH NO OBSERVED ADVERSE EVENTS TO DATE IN PHASE 1/2 CLINICAL TRIAL OF RTX-240 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results